NitroMed announces closing of its acquisition by Deerfield Management
Pursuant to the terms of the previously announced agreement and plan of merger, at the effective time of the merger each share of NitroMed common stock was automatically
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.